Full Press Release Details
Moleculin Announces Significant
Discovery with Potential to Treat Pancreatic Cancer
Metabolic Inhibitor Shows
Greater Ability to Kill Pancreatic Cancer Cell Lines
HOUSTON - June 21, 2017 - Moleculin
Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused
on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System
on behalf of the M.D. Anderson Cancer Center, today announced the discovery of a metabolic inhibitor with the potential to treat
"We've received a lot of attention
from the scientific community for our glucose decoy technology (WP1122 Portfolio, Moleculin Presents Preclinical Data of Novel
Inhibitor of Glycolysis at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, December 13, 2016) as
a potential means to starve tumors to death by exploiting their hyper-dependence on glycolysis for energy production," commented
Walter Klemp, Chairman and CEO of Moleculin, "and now we have identified possible new properties of our compound WP1234,
a modification to WP1122. In pre-clinical testing, WP1234 has shown improved drug characteristics when compared with WP1122 and
a 20 to 50-fold greater ability to kill pancreatic cancer cell lines when compared with traditional inhibitors of glycolysis. We
know that pancreatic cancer thrives even in a reduced oxygen environment, which indicates it may be highly dependent on glycolysis
to survive. This discovery now makes WP1234 a promising drug candidate to be studied for the treatment of pancreatic cancer."
Mr. Klemp continued: "Pancreatic
cancer is still considered largely untreatable, so even modest gains in treating this disease could represent a significant clinical
benefit. WP1234 improves on known inhibitors for glycolysis by increasing drug circulation time, which should increase the potential
for drug uptake by and destruction of tumor cells. We are excited about the potential to pursue development opportunities with
WP1234 for the treatment of pancreatic cancer. We are also pleased to report that this discovery was the direct result of our ongoing
collaboration with MD Anderson Cancer Center and the science team there will be presenting detailed findings to the scientific
community in the near future."
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a preclinical
stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries
made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, an anthracycline being studied for the treatment
of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two preclinical small molecule
portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of
the patient's own immune system. The other portfolio targets the metabolism of tumors.
For more information about the Company, please visit http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release
are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, the ability of WP1234 to become a safe and effective drug for pancreatic cancer
in humans and the potential for that to translate into a significant clinical benefit. These statements relate to future events,
future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed
or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes
to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties,
and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed
with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our
other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We
undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring
after its date or to reflect the occurrence of unanticipated events.
Chief Operating Officer